US 12,357,582 B2
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
Robert K. Prud'homme, Princeton, NJ (US); Kurt D. Ristroph, Princeton, NJ (US); Nathalie M. Pinkerton, Princeton, NJ (US); Hoang D. Lu, Princeton, NJ (US); and Paradorn Rummaneethorn, Princeton, NJ (US)
Assigned to The Trustees of Princeton University, Princeton, NJ (US)
Appl. No. 16/761,140
Filed by The Trustees of Princeton University, Princeton, NJ (US)
PCT Filed Nov. 2, 2018, PCT No. PCT/US2018/058869
§ 371(c)(1), (2) Date May 1, 2020,
PCT Pub. No. WO2019/090030, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/581,394, filed on Nov. 3, 2017.
Prior Publication US 2020/0268679 A1, Aug. 27, 2020
Int. Cl. A61K 9/51 (2006.01); A61K 31/5377 (2006.01); A61K 31/7036 (2006.01); A61K 38/10 (2006.01); A61K 38/12 (2006.01); A61K 38/38 (2006.01); A61K 38/47 (2006.01)
CPC A61K 9/5153 (2013.01) [A61K 9/5161 (2013.01); A61K 9/5192 (2013.01); A61K 31/5377 (2013.01); A61K 31/7036 (2013.01); A61K 38/10 (2013.01); A61K 38/12 (2013.01); A61K 38/38 (2013.01); A61K 38/47 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A set of nanoparticles, comprising:
nanoparticles comprising
a modified salt comprising an active pharmaceutical ingredient (API) ion paired with a hydrophobic counterion; and
a nanoparticle encapsulant material substantially surrounding the modified salt,
wherein the nanoparticle encapsulant material comprises polycaprolactone-block-polyethylene glycol block copolymer (PCL-b-PEG),
wherein the active pharmaceutical ingredient (API) is a water-soluble linear cationic peptide of a molecular weight of from 1,422 Da to 2,000 Da and of at least 14% basic amino acids of amino acids,
wherein the hydrophobic counterion is an alkyl sulfate, and
wherein the set of nanoparticles has a Z-average diameter of at least 120 nm.